DICER1, DROSHA and mirnas in patients with non-small cell lung cancer: implications for outcomes and histologic classification For Peer Review
|
|
- Cuthbert Harrington
- 5 years ago
- Views:
Transcription
1 Carcinogenesis Advance Access published January, DICER, DROSHA and mirnas in patients with non-small cell lung cancer: implications for outcomes and histologic classification Journal: Carcinogenesis Manuscript ID: CARCIN--0.R Manuscript Type: Original Manuscript Date Submitted by the Author: 0-Jan- Complete List of Authors: Díaz-García, C. Vanesa; Hospital Universitario de Octubre, Oncology; Instituto de Investigación Hospital de Octubre, Oncology Agudo-López, Alba; Hospital Universitario de Octubre, Oncology; Instituto de Investigación Hospital de Octubre, Oncology Pérez, Carlos; Hospital Universitario de Octubre, Oncology; Instituto de Investigación Hospital de Octubre, Oncology López-Martín, José; Hospital Universitario de Octubre, Oncology Rodríguez-Peralto, José; Hospital Universitario de Octubre, Pathology; Instituto de Investigación Hospital de Octubre, Oncology de Castro, Javier; Hospital Universitario La Paz, Oncology Cortijo, Ana; Hospital Universitario de Octubre, Oncology Martínez-Villanueva, Miriam; Hospital Universitario de Octubre, Oncology Iglesias, Lara; Hospital Universitario de Octubre, Oncology García-Carbonero, Rocío; Hospital Universitario Virgen del Rocío, Oncology Fresno-Vara, Juan; Instituto de Genética Médica y Molecular-INGEMM, Laboratory of Molecular Pathology and Oncology Gámez-Pozo, Angelo; Instituto de Genética Médica y Molecular-INGEMM, Laboratory of Molecular Pathology and Oncology Palacios, José; Hospital Universitario Virgen del Rocío, Pathology Cortés-Funes, Hernán; Hospital Universitario de Octubre, Oncology Paz-Ares, Luis; Hospital Universitario Virgen del Rocío, Oncology Agulló-Ortuño, Mª Teresa; Hospital Universitario de Octubre, Oncology; Instituto de Investigación Hospital de Octubre, Oncology Downloaded from at Pennsylvania State University on February, Keywords: lung cancer, interference machinery, mirnas, prognosis
2 Page of Carcinogenesis DICER, DROSHA, and mirnas in NSCLC DICER, DROSHA and mirnas in patients with non-small cell lung cancer: implications for outcomes and histologic classification Short Title: DICER, DROSHA, and mirnas in NSCLC. C. Vanesa Díaz-García,, Alba Agudo-López,, Carlos Pérez,, José A. López-Martín,, J. Luis Rodríguez-Peralto,, Javier de Castro, Ana Cortijo,, Miriam Martínez-Villanueva,, Lara Iglesias, Rocío García-Carbonero, Juan A. Fresno Vara, Angelo Gámez-Pozo, José Palacios, Hernán Cortés-Funes, Luis Paz-Ares,, M. Teresa Agulló-Ortuño,, *, Oncology Department. Hospital Universitario de Octubre, Madrid, 0, Spain. Instituto de Investigación Hospital de Octubre, Madrid, 0,Spain Pathology Department. Hospital Universitario de Octubre, Madrid, 0, Spain. Oncology Department. Hospital Universitario La Paz, Madrid, 0, Spain. Oncology Department. Hospital Universitario Virgen del Rocío, Sevilla, 0, Spain. Laboratory of Molecular Pathology and Oncology. Instituto de Genética Médica y Molecular- INGEMM. Instituto de Investigación Hospital Universitario La Paz-IdiPAZ, Madrid, 0, Spain. Pathology Department. Hospital Universitario Virgen del Rocío, Sevilla, 0, Spain. Present address: Clinical Research Support Office. MD Anderson Cancer Center, Madrid, 0, Spain. Present address: Clinical Pathology Department. Hospital Universitario Virgen de la Arrixaca, Murcia, 0, Spain. * To whom correspondence should be addressed. Tel: + 0; Fax: + 0; agullo@ho.es. Correspondence may also be addressed to Mª Teresa Agulló-Ortuño, Tel: + 0; Fax: + 0; agullo@ho.es These authors contributed equally to this work. Downloaded from at Pennsylvania State University on February,
3 Page of DICER, DROSHA, and mirnas in NSCLC Abstract The clinical and functional significance of RNA interference machinery in lung cancer is poorly understood. Besides, micrornas have the potential to serve both as biomarkers and therapeutic agents, by personalizing diagnosis and therapy. In this study, we investigated whether the expression levels of DICER and DROSHA, components of the RNA-interference machinery, can predict survival, and whether microrna expression profiles can differentiate histologic subtypes in non-small cell lung cancer (NSCLC). Levels of DICER, DROSHA and five different micrornas was measured in NSCLC specimens (N=) by qrt-pcr assay, and correlated with clinical outcomes. Low expression of DROSHA was associated with an increased median survival (. vs. months; P=0.0). Also, high DROSHA expression was associated with decreased median survival in the following subgroups: adenocarcinoma (P=0.0), grade III tumors (P=0.0), and low stage patients (P=0.0). In multivariate analyses we found two independent predictors of reduced disease-specific survival: high DROSHA expression (HR=.; P=0.0), and advanced tumor stage (HR=.; P=0.0). In general, the overall tumor mirna expression was downregulated inour cohort compared to normal tissues. Expression level of hsa-let-a (P=0.00) and mir- (P=0.00) mirna were significantly higher in squamous cell carcinoma than in adenocarcinoma samples. The present study supports the value of the expression profiling of the components of the mirna-processing machinery in the prognosis of NSCLC patients, especially DROSHA expression levels. In addition, differential expression of mirnas, such as hsa-let-a and mir- may be helpful tools in the histologic subclassification of NSCLC. Downloaded from at Pennsylvania State University on February,
4 Page of Carcinogenesis DICER, DROSHA, and mirnas in NSCLC Introduction Lung cancer is the leading cause of cancer-related death worldwide (). Pulmonary neoplasias are classified as small (SCLC) or non-small cell lung cancer (NSCLC), the latter comprising a heterogeneous group which is also subclassified in different morphological varieties mainly, squamous cell carcinoma (SCC), adenocarcinoma (ADC) and large cell carcinoma (LCC). The emerging treatment revolution determined by new targeted therapies stresses the importance of accurate tumor subtyping as a mandatory step in the clinical work-up of these patients. Moreover, the discovery that gene expression can be altered through RNA interference () has stimulated research on the role of RNA interference in the development of cancer. Regulation of gene expression through RNA interference occurs by means of microrna (mirna) or small interfering RNA (sirna). Expression profiling of many micrornas in various normal and diseased tissues has demonstrated unique spatial and temporal expression patterns. Some mirnas have been functionally characterized as oncogenes or tumor suppressor genes (, ). Also, mirnas are involved in tissue differentiation during both normal development and carcinogenesis, and mirna expression profiles have been seen not only as a new class of diagnostic and prognostic tools but also as candidates for pharmacological targeting (, -0). Most importantly, mirna expression signatures in both tumor cells and peripheral blood cells from cancer patients, can predict outcome (-). The biogenesis of mirna has been reviewed extensively (Supplementary Figure ) and its pathway components could be either misexpressed or mutated in tumors. A clear consequence is that mirna overexpression could result in downregulation of tumor suppressor genes, whereas their underexpression could lead to oncogene upregulation. Their functional association with cancer, small gene size and potential to simultaneously affect a multitude of genes makes them unique candidate loci for conferring cancer susceptibility, as a small genetic change in a mirna sequence can theoretically lead to widespread phenotypic effects. The RNases DICER and DROSHA serve as key regulatory proteins in mirna biogenesis pathway and their alterations may contribute to widespread mirna deregulation in cancer (). Thus, we examined whether altered levels of DICER and DROSHA mrna, components of the RNAinterference machinery, are associated with clinical outcome in lung cancer. Furthermore, we checked out the role of several mirnas in differentiating between the two major NSCLC subtypes in human tumor samples, and their potential as biomarkers for lung cancer risk stratification in order to validate the reliability of these novel markers in routine diagnostic samples. Downloaded from at Pennsylvania State University on February,
5 Page of DICER, DROSHA, and mirnas in NSCLC Materials and methods Tumor Samples Patients were eligible if they had been diagnosed NSCLC, surgically resected, never received radiotherapy or chemotherapy and if there was evaluable tumor tissue available. From 00 to 0, we selected patients at centers for participation in the study: de Octubre University Hospital (N=), La Paz University Hospital (N=) and Virgen del Rocio University Hospital (N=). In addition, we obtained eight benign ephitelial-lung tissues from de Octubre University Hospital Tissue Bank. Specimens were snap-frozen at -0ºC until used. Histologic preparations of tumor sections were examined by pathologists without any information about the outcome, and only tissue samples with tumor content >0% were selected. The study was approved by the local Ethics Committees and Commissions of Research (Comité Ético de Investigación Clínica del Hospital Universitario de Octubre), and permission was obtained for the use of all samples. Real-time quantitative reverse transcription-pcr Samples were blinded and coded before any laboratory procedure was started. Quantitative RT-PCR was performed with the use of the TaqMan gene-expression assay and TaqMan MicroRNA assay kits (Applied Biosystems) according to the manufacturer s instructions. Amplifications were carried out on the Applied Biosystem 00 RT-PCR system, and relative gene expression values were calculated by the Ct method (Sequence Detection System.0.). Results from analysis, done in triplicate, are expressed relative to expression levels of TATA box binding protein (TBP) for DICER and DROSHA, and small nuclear RNA U (RNUB) for mirnas. The final mrna levels were converted to ratios of decreased expression ( ) or increased expression (>) relative to levels of respective mrna or mirna in normal lung epithelium. Immunohistochemical Analyses The immunohistochemical experiments (IHC) were performed on µm-thick formalin-fixed and paraffin embedded (FFPE) tissue sections. All steps were performed on the Leica Bond III automated system (Leica Microsystems) according to the manufacturer s instructions. In brief, specimens were deparaffinized and antigen was retrieved on the instrument. All slides were incubated with primary antibodies against DICER (diluted :0, Abcam) or DROSHA (:00, Abcam) for minutes, Downloaded from at Pennsylvania State University on February,
6 Page of Carcinogenesis DICER, DROSHA, and mirnas in NSCLC followed by incubation with a mouse-rabbit-horseradish peroxidase polymer and, - diaminobenzidine substrate. The stained slides were scored by two investigators who were unaware of the RT-PCR results. Staining intensity was given as no or very weak staining (score 0), weak to moderate (score ) and deep staining (score ) at x00 magnification. The percentage of positive cells was scored: 0 (0%-0%), (%-%), (%-0%), and (%-00%). We defined the IHC staining score as the sum of the intensity and percentage scores. Tumors were categorized into lowexpression group (score= 0~), and high-expression group (score= ~). The scores from two independent investigators were compared and disagreements were resolved by consensus. Validation Analysis The relation between levels of DICER and DROSHA mrna and survival among patients with lung cancer was examined in existing microarray data sets of samples (GEO accession number: GSE, and GSE0), that have been profiled with an Affymetrix GeneChip assay (HG-U Plus.0) (, ). Probe sets _at and _at were used to measure DICER and DROSHA expression, respectively. Statistical Analysis Statistical analysis was performed using SPSS.0 (Chicago, IL, USA). Kaplan-Meier plots were constructed and log-rank test was used to determine differences in survival and disease-free survival curves. Multivariate analyses with a Cox proportional hazard model were used to examine the effects of DICER, DROSHA and mirna expression on death while adjusting for other covariates. Student s t-test was used for comparison between two groups and U Mann-Whitney test was used to compare groups which did not conform to the assumption of normality (Kolmogorov-Smirnov test). Contingency tables and Fisher s exact test were used to statistically evaluate the relationship between death and categorical variables. All the statistical tests were conducted at the two-sided 0.0 level of significance. Results DICER and DROSHA are deregulated in NSCLC Downloaded from at Pennsylvania State University on February,
7 Page of DICER, DROSHA, and mirnas in NSCLC Levels of DICER mrna in cancer specimens followed a normal distribution (P= 0.). However, the distribution of DROSHA mrna levels was bimodal (P= 0.000) with two peaks in the ratio (0. and.). DICER and DROSA expression varied among cancer specimen; % had decreased DICER mrna and % had increased DROSHA mrna (Supplementary Table ). We did not find a significant correlation between DICER and DROSHA expression levels in NSCLC tumors (P= 0.0). The protein levels of DICER and DROSHA were also examined by immunohistochemical staining in a subgroup of samples (Supplementary Figure ). The results were consistent with the mrna expression levels for both DICER (Spearman s rho= 0., P= 0.000) and DROSHA (Spearman s rho= 0.0, P= 0.00). Analysis of Clinical Associations Table lists the baseline characteristics of all patients with NSCLC. Clinical outcome data were obtained from patient records. At a median follow-up of months (range -), overall -year survival was.% and patients (.%) had relapsed. At the end of the study, most patients were alive without disease (.%). In univariate analyses, neither DICER nor DROSHA mrna levels were significantly associated with age, tobacco consumption, tumor histology, tumor grade or tumor stage (Table ). Death from any cause was associated with high levels of DROSHA mrna (. ± 0. vs. ± 0., P= 0.0;.% of dead patients), but we found no relationship to the levels of DICER mrna (P= 0.). We examined whether the expression levels of DICER and DROSHA were associated with patient survival after surgery: Kaplan-Meier survival curves show that, even though the median overall survival (OS) was substantially reduced among patients whose tumor had low level of DICER mrna, did not reach statistical significance (P= 0., Figure.A). On the other hand, Kaplan-Meier curves demonstrated that the probability of survival was significantly lower for the group of patients with high levels of DROSHA mrna (. vs.. months; P= 0.0, Figure.B). Comparison among other subgroups of patients is shown in Suplementary Figure. We did not find any significant difference in the expression levels of DICER or DROSHA between SCC and ADC histology (P= 0.0 and P= 0. respectively). Nevertheless, the median OS was significant reduced among ADC patients with high levels of DROSHA expression (not reached, vs. months, P= 0.0) (Figure.C), and thus, risk of death was associated with high levels of Downloaded from at Pennsylvania State University on February,
8 Page of Carcinogenesis DICER, DROSHA, and mirnas in NSCLC DROSHA mrna in ADC patients (. ± 0. vs. ± 0., P= 0.0; 0% of dead ADC patients). However, these relationships were not found in SCC patients (data not shown). Similar to the histology, there were no differences in DICER or DROSHA expression between high- and low-grade tumors (P= 0. and P= 0.). Nevertheless, the median OS was significant reduced among grade III patients with high levels of DROSHA expression (not reached vs. months, P= 0.0) (Figure.D). Neither were differences between high- and low-stage tumors (P= 0., DICER and P= 0., DROSHA), although the OS was significantly reduced among low stage (I or II) patients with high levels of DROSHA expression (P= 0.0, Figure.E). To validate our findings, we used previously reported microarray data to compare expression of DICER and DROSHA with OS, in two different cohorts of lung cancer patients. In the first validation cohort () and similar to our initial findings, increased survival was associated with high expression of DICER mrna (not reached vs. months, P= 0.0) and low DROSHA mrna (. vs. months, P= 0.0) (Figure.F). Also, in the second validation cohort (), increased OS was associated with high expression of DICER mrna (P= 0.000) and low expression of DROSHA mrna (P=0.00), (Figure.G). The latter validation cohort consisted of patients with very early ADC stage (I or II) and the median survival time was not reached. In multivariate analyses (including age, sex, tumor stage, grade, histology, and DICER and DROSHA mrna levels), only tumor stage (III-IV vs others, P=0.0) and DROSHA mrna expression (P=0.0) were selected as independent prognostic variables (Table ). An increased DROSHA mrna level was a significant predictive factor for poor prognosis (HR=.; %CI,.0 to.; P=0.0), whereas DICER expression level did not show a significant association with survival (HR= 0.; %CI, 0. to.; P=0.). mirna expression profiling Several mirnas have recently been linked to tumorigenesis in many types of tumors (). In view of this, we decided to study in samples from our cohort in which sufficient RNA were available (N= ), the expression of some of the most relevant lung cancer-related mirna described in the literature. In particular, we studied hsa-let-a, mir-0c, mir-, mir- and mir- expression levels by qrt- PCR. The overall tumor mirna expression was downregulated compared to normal tissue (Supplementary Table ). The qrt-pcr analysis revealed that hsa-let-a (P=0.00) and mir- Downloaded from at Pennsylvania State University on February,
9 Page of DICER, DROSHA, and mirnas in NSCLC (P=0.00) expression levels were significantly higher in SCC than in ADC, (Figure.A). The only mirna with higher expression levels in ADC was mir- (P=0.), and at least -fold upregulation of mir expression was found in.% of cases. There were no significant differences in mirna expression levels depending on the tumor stage or tumor grade. Given the different mirna profiles by histology, we conducted survival analyses in the two histology groups separately. We did not find significant differences in neither OS nor disease free survival according to the mirna expression level in both histological subtypes. However, OS in our total population was higher in those patients with higher hsa-let-a (. ±. vs. ±. months, P=0.0) and higher mir-0c (. ±. vs 0. ±. months, P= 0.0) expression levels. In our study, increased DROSHA expression was associated with poor prognosis in lung cancer patients. Curiously, despite a.-fold increase in DROSHA expression in lung cancer samples, all studied mirna expression levels were decreased in this subpopulation. Interestingly, when we divided our population according to DICER and DROSHA expression levels (low and high), the mirna expression differences between the two histological types occurred only when DICER or DROSHA levels were below benign ephitelial-lung tissues levels (Figure.B). We also calculated pairwise correlation values for the mirnas and DICER and DROSHA: hsa-let- a showed a high correlation value with mir- (ρ= 0.0), with mir-0c (ρ= 0.), and with mir- (ρ= 0.). mir-0c and mir- showed a Spearman s correlation value of 0. (Supplementary Table ). There was no correlation between DICER and DROSHA expression (ρ= 0.), however there was an inversely correlation between DICER and hsa-let-a (ρ= -0.), and mir-0 (ρ= -0,0), and mir- (ρ= -0.). Also, DROSHA showed an inverse correlation value with hsa-let-a (ρ= -0.), and with mir- (ρ= -0,) (Supplementary Table ). Discussion The production of mature microrna involves a cascade of events that are closely linked to the functions of DICER and DROSHA. Likewise, it is possible that deregulated mirna expression, observed in several types of tumor (), is secondary to defective RNA silencing machinery. In our study, we found that DICER and DROSHA expression levels are variable among NSCLC specimens, and play a significant role in OS, especially DROSHA mrna expression. Levels of gene and proteomic expression were examined by qrt-pcr and IHC, with high values of correlation. Downloaded from at Pennsylvania State University on February,
10 Page of Carcinogenesis DICER, DROSHA, and mirnas in NSCLC We found that low DICER expression levels were associated with poor outcome, although this was not statistically significant. Previously, downregulation or lower expression of DICER was found to be significantly associated with NSCLC survival (), advanced tumor stages of ovarian carcinomas (), or epithelial skin cancer (), while upregulation of DICER has been described for prostate adenocarcinomas and lung carcinomas (, ). Chiosea et al. () showed that in lung ADC, DICER was downregulated in areas of invasion and in cases of advanced disease. Similar to Sand et al. (), we found a highly significant upregulation of DROSHA expression in NSCLC samples. This result supports the hypothesis that patients with lung cancer may show an alteration in DROSHA expression levels as DROSHA was overexpressed in both the SCC and ADC histologic groups. Moreover, we show an association between high DROSHA expression and poor clinical outcome in both high grade tumors and early stage tumors, suggesting that DROSHA exerts its influence most profoundly within these subgroups of tumors. High DICER and high DROSHA expression were correlated with poor prognostic factors in prostate cancer and esophageal carcinoma (, ). There are several plausible explanations for the divergent expression patterns of DICER and DROSHA among different solid tumors and how they relate to clinical and pathologic variables. Direct interactions with other components of the RNAinterference cascade could result in compensatory alterations of DICER or DROSHA expression in the presence of mutated cofactors such as genes for DGCR, XPO, and AGO (, -). The findings described in this study indicated that the expression levels of DROSHA appeared to have a significant impact (P= 0.0) on the postoperative survival of NSCLC patients, independent of disease stage (P= 0.0). Although there are some differences in the statistical significance levels, we believe that our study has been validated in two independent cohorts of patients, since Kaplan-Meier survival analysis of these validation cohorts showed a significant survival disadvantage for patients whose tumors expressed low DICER and high DROSHA mrna levels. Thus, increased expression of DROSHA appears to be clinically useful for the prognosis of lung cancer patients. In addition, other factors may underlie the potential biological effects of increased DROSHA expression in lung cancer cells. Several large-scale mirna expression studies have indicated that global mirna levels are reduced in tumor samples in comparison with normal tissues (). Our results are consistent with this, and the five mirna studied here show lower expression levels in our set of tumor samples than in normal Downloaded from at Pennsylvania State University on February,
11 Page 0 of DICER, DROSHA, and mirnas in NSCLC 0 tissues. Interestingly, the rate of reduction was much more pronounced in ADC than in SCC tumors, with statistically significant differences in the expression levels of hsa-let-a and mir- between both histological types. This pattern suggests that these mirnas may be more relevant for ADC tumorigenesis because they exhibit poor expression in this tumor type. Even more interesting is that these differences of expression between the two histological types only hold when DICER or DROSHA expression levels are below normal tissues values. That is, different mirna expression profiles between ADC and SCC subtypes are evident mainly when the mirna machinery is defective. On the other hand, we must take into account the inverse correlation between DICER and hsa-let-a, mir-0 and mir- expression levels, and also between DROSHA and hsa-let-a and mir- expression levels. A possible explanation could be that these mirnas suppress, somewhat, the expression of DICER and DROSHA, but this assertion must be tested further, and new experiments should be designed. We must consider that an examination of any individual or small series of mirnas may not reflect the complexity of changes in mirna expression participating in clinical tumor biology (). In addition, mirna could have varying regulatory effects independent of alterations in the RNA-processing machinery (0-). Posttranscriptional regulation of mirna processing also plays an important role in the regulation of mirna expression (, ), but a connection of these modifications to tumorigenesis has not yet been definitive. Moreover, one-half of the mirnas have been aligned to genomic fragile sites or regions associated with cancer. Finally, several studies suggest that mirna function is determined by the specific cellular context (). More important, mirna overexpression could result in downregulation of tumor suppressor genes, whereas their underexpression could lead to oncogene up-regulation. For this reason, some mirnas have been shown to function as oncogenes while others such as tumor suppressors: mir- and mir- are examples of mirna described as oncogenes, and hsa-let-a and mir-0c as tumor suppressor mirna (). In our set of patients, OS was higher in patients with hsa-let-a or mir-0c overexpressed, and these results are in accordance with the function as tumor suppressors of these mirnas. We found higher mir- expression levels in SCC compared to ADC samples, and this difference was highly significant statistically. Similarly Bandi et al. () detected overexpression of mir- in % of NSCLC tumors. Tan et al. () described a -microrna classifier that can distinguish cancerous SCC lesions from adjacent normal tissues; however none of the mirna described match those Downloaded from at Pennsylvania State University on February,
12 Page of Carcinogenesis DICER, DROSHA, and mirnas in NSCLC studied here. They also showed that hsa-mir- directly targets the DICER -UTR and repressed their expression. Moreover, high expression of hsa-mir- was associated with poor survival, which is consistent with our data, given that low levels of DICER correlates with shortened postoperative survival. Voortman et al. () studied a panel of mirna by qrt-pcr in FFPE tumor specimens from International Adjuvant Lung Cancer Trial (IALT) patients. No significant association was found between any of the tested mirnas and survival, and expression patterns examined were neither predictive nor prognostic in this large patient cohort. In conclusion, the present study supports the value of the expression profiling of the mirnaprocessing machinery components in the prognosis of NSCLC patients, especially DROSHA expression levels. Whether alterations in the mirna machinery are associated with the risk of lung cancer or whether DICER and DROSHA expression levels are concomitantly altered due to lung cancer, remains unclear and needs to be addressed further in future studies. In recent years, no biomarker has generated as much interest as mirnas, which have been considered for a variety of purposes, and we have proved that differential expression of some mirna such as hsa-let-a, and mir- are reliable tools in the subclassification of NSCLC. Thus, mirnas could become powerful therapeutic tools in the near future. However, the validation of these findings in multiple cohorts and the testing of their applicability to different ethnic populations are also required. Supplementary material Supplementary Figures, and, and Supplementary Tables, and, can be found at Funding This work was supported by Instituto de Salud Carlos III (grant numbers PI0, PI to L.P.- A., PI0 to R.G.-C., PI00 to J.P.), Spain. A.A.-L. and C.P. are fellows supported by Ministerio de Sanidad y Política Social (TRA-), Spain. V.D.-G. is supported by Fundación Mutua Madrileña (0/0), Spain. Downloaded from at Pennsylvania State University on February,
13 Page of DICER, DROSHA, and mirnas in NSCLC Acknowledgements We would to thank Juan Carlos Rubio of Genomic Department (Instituto de Investigación Hospital de Octubre, Madrid) for his invaluable technical assistance. Conflict of Interest Statement: None declared. References. Jemal, A. et al. () Global cancer statistics. CA Cancer J Clin.,, -0. /. Fire, A. et al. () Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature, (), 0-.. Farazi, T.A. et al. () mirnas in human cancer. J Pathol.,,0-.. Markou, A. et al. () Prognostic, therapeutic and diagnostic potential of micrornas in non-small cell lung cancer. Clin Chem Lab Med.,, -.. Lu, J. et al. (0) MicroRNA expression profiles classify human cancers. Nature,, -.. Iorio, M.V. et al. (0) MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol.,, -.. Mascaux, C. et al. (0) Evolution of microrna expression during human bronchial squamous carcinogenesis. Eur Respir J.,,-.. Landi, M.T. et al. (0) MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res.,, 0-.. Liu, X. et al. () Involvement of micrornas in lung cancer biology and therapy. Transl Res.,, Fassina, A. et al. () Classification of non-small cell lung carcinoma in transthoracic needle specimens using microrna expression profiling. Chest,, 0-.. Yu, S.L. et al. (0) MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell,, -.. Showe, M.K. et al. (0) Gene expression profiles in peripheral blood mononuclear cells can distinguish patients with non-small cell lung cancer from patients with nonmalignant lung disease. Cancer Res.,, -0.. Roa, W. et al. (0) Identification of a new microrna expression profile as a potential cancer screening tool. Clin Invest Med.,, E.. Leidinger, P. et al. () Specific peripheral mirna profiles for distinguishing lung cancer from COPD. Lung Cancer,, -. Downloaded from at Pennsylvania State University on February,
14 Page of Carcinogenesis DICER, DROSHA, and mirnas in NSCLC. Kumar, M.S. et al. (0) Impaired microrna processing enhances cellular transformation and tumorigenesis. Nat Gene.,, -.. Bild, A.H. et al. (0) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature,, -.. Okayama, H. et al. () Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. Cancer Res.,, Nelson, K.M. et al. (0) MicroRNAs and cancer: past, present, and potential future. Mol Cancer Ther.,, -.. Zhang, L. et al. (0) micrornas exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A, 0, -.. Karube, Y. et al. (0) Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci.,,-.. Merritt, W.M. et al. (0) Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med.,, -0.. Sand, M. et al. (0) Expression levels of the microrna processing enzymes Drosha and dicer in epithelial skin cancer. Cancer Invest.,, -.. Chiosea, S. et al. (0) Up-regulation of dicer, a component of the MicroRNA machinery, in prostate adenocarcinoma. Am J Pathol.,, -.. Chiosea, S. et al. (0) Overexpression of Dicer in precursor lesions of lung adenocarcinoma. Cancer Res.,, -0.. Sugito, N. et al. (0) RNASEN regulates cell proliferation and affects survival in esophageal cancer patients. Clin Cancer Res.,, -.. Horikawa, Y. et al. (0) Single nucleotide polymorphisms of microrna machinery genes modify the risk of renal cell carcinoma. Clin Cancer Res.,, -.. Melo, S.A. et al. (0) A TARBP mutation in human cancer impairs microrna processing and DICER function. Nat Genet.,, -0.. Davis-Dusenbery, B. et al. () MicroRNA in Cancer: The Involvement of Aberrant MicroRNA Biogenesis Regulatory Pathways. Genes & Cancer,, Lee, E.J., et al. (0) Systematic evaluation of microrna processing patterns in tissues, cell lines, and tumors. RNA,, Suzuki, H.I. et al. (0) Modulation of microrna processing by p. Nature,, -.. Su, X. et al. (0) TAp suppresses metastasis through coordinate regulation of Dicer and mirnas. Nature,, -0.. Chiosea, S.I. et al. (0) Mucoepidermoid carcinoma of upper aerodigestive tract: clinicopathologic study of cases with immunohistochemical analysis of Dicer expression. Virchows Arch.,, -.. Ryan, B.M. et al. (0) Genetic variation in microrna networks: the implications for cancer research. Nat Rev Cancer, 0, -. Downloaded from at Pennsylvania State University on February,
15 Page of DICER, DROSHA, and mirnas in NSCLC. Garofalo, M. et al. () micrornas: Master regulators as potential therapeutics in cancer. Annu Rev Pharmacol Toxicol.,, -.. Bandi, N. et al. (0) mir-a and mir- are implicated in cell cycle regulation in a Rbdependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res.,, -.. Tan, X. et al. () A -microrna signature for lung squamous cell carcinoma diagnosis and hsa-mir- for prognosis. Clin Cancer Res.,, 0-.. Voortman, J. et al. (0) MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res., 0, -. Downloaded from at Pennsylvania State University on February,
16 Page of Carcinogenesis DICER, DROSHA, and mirnas in NSCLC TABLES Table. Clinicopathologic characteristics of patients. a NA: not available Characteristic (N = ) N (%) Age at diagnosis (years) Mean. Range - Gender Male 0 (.) Female (0.) Tobacco (N = 0) Non smokers (0.0) Former smokers (.) Current smokers (.) Histology Squamous (.) Adenocarcinoma (.) Large cell (.0) Other (.) Histologic differentiation Well differentiated (grade I) (.) Moderately differentiated (grade II) (.) Poorly/un-differentiated (grade III) (.) NOS (Not otherwise specified) (.) Tumor Stage I (A and B) (.0) II (A and B) (.) III (A and B) (.) IV (.) NA a (0.) Disease status Alive with disease (0.) Alive without disease (.) Dead from disease (.) Downloaded from at Pennsylvania State University on February,
17 Page of DICER, DROSHA, and mirnas in NSCLC Table. Correlation of Clinical and Pathological Features with DICER and DROSHA Messenger RNA (mrna) Levels in Patients with lung cancer. Plus-minus values are means ± SD. P values were calculated after missing values were excluded. DICER mrna Level Low High P value Low High P value Variable (N=) (N=) (N=) (N=) Age yr.±..±. 0..±..±0. 0. Tobacco N (%) Non smokers (.) (.) 0. (.) (.) 0. Former smokers (.) (.) (.) (.) Current smokers (.) (.) (.) 0 (.) Histology N (%) Squamous (.) (.) 0. 0 (.) (.) 0. Adenocarcinoma (.) (.) (.) (.) Large cell (.) (0.) (.) (.) Others (.) (0.) (.) (.) Histol. Differentiation N (%) Well diff. (grade I) (.) 0 (.) 0. (.) 0 (.) 0. Moderately diff. (grade II) (.) (.) (.) (.) Poorly/undiff. (grade III) (.) (.0) (.) (.) Tumor stage N (%) I (.) (.) 0. (.) (.) 0. II (.0) (.) (.) (.0) III (.) (.) (.) (0.0) IV (.) 0 (.) (.) DROSHA mrna Level Downloaded from at Pennsylvania State University on February,
18 Page of Carcinogenesis DICER, DROSHA, and mirnas in NSCLC Table. Multivariate Analysis Results of Independent Prognostic Factors in Patients with NSCLC. Hazard Ratio for Death P value Factor (% CI) High DROSHA expression. (.0-.) 0.0 High DICER expression 0. (0.-.) 0. Increased age.0 (0.-.0) 0. Male. (0.-.) 0. Adenocarcinoma histology.0 (0.-.) 0. Tumor stage III or IV. (.-.) 0.0 High-grade tumor. (0.-.) 0. Downloaded from at Pennsylvania State University on February,
19 Page of DICER, DROSHA, and mirnas in NSCLC TABLE AND FIGURES LEGENDS Table. Clinicopathologic characteristics of patients. Table. Correlation of Clinical and Pathological Features with DICER and DROSHA Messenger RNA (mrna) Levels in Patients with lung cancer. Plus-minus values are means ± SD. P values were calculated after missing values were excluded. Table. Multivariate Analysis Results of Independent Prognostic Factors in Patients with Lung Cancer. Fig.. Kaplan-Meier survival curves and log-rank analysis for patients according to tumor expression of DICER and DROSHA. (A, B) Survival curves in the study cohort. (C) In adenocarcinoma patients. (D) In patients with tumor grade III. (E) In patients with lung cancer stage I or II. (F, G) Curves from validation analysis are also shown for the expression of DICER and DROSHA in independent cohorts of patients with lung cancer. Fig. : (A) Relative fold of hsa-let-a, mir-0c, mir-, mir- and mir- levels in lung ADC (bright gray) and SCC (dark gray) samples. MicroRNA expression profiles significantly differed between SCC and ADC. (B) Differences in hsa-let-a and mir expression levels in SCC (N= ) and ADC (N=) samples with low expression of DICER and DROSHA. Columns, representative images of reactions run in triplicate; bars, SD. P< 0.0. Downloaded from at Pennsylvania State University on February,
20 Page of Carcinogenesis Fig.. A % of Survival,0,,,, 0,0 0 Months after surgery Nº at Risk Events Months 0 0 Low DICER High DICER 0 C % of Survival,0,,,, 0,0 0 P= 0. P= 0.0 Months after surgery (AD) High DICER Low DICER 0 Low DROSHA High DROSHA Nº at Risk Events Months 0 0 Low DROSHA High DROSHA B % of Survival D % of Survival,0,,,, 0,0,0,,,, 0,0 0 0 P= 0.0 Months after surgery Nº at Risk Events Months 0 0 Low DROSHA High DROSHA P= 0.0 Low DROSHA 0 0 Months after surgery (Grade III) High DROSHA Low DROSHA High DROSHA Nº at Risk Events Months 0 0 Low DROSHA 0 High DROSHA Downloaded from at Pennsylvania State University on February,
21 Page of E % of Survival,0,,,, 0,0 0 0 Month after surgery (Stage I or II) Nº at Risk Events Months 0 0 Low DROSHA High DROSHA 0 0 F % of Survival,0,,,, 0,0 0 P= 0.0 First Validation Cohort P= 0.0 Months after surgery Low DROSHA High DROSHA High DICER 0 00 Low DICER 00 Nº at Risk Events Months 0 0 Low DICER 0 High DICER 0 % of Survival,0,,,,,0 0 P= 0.0 Months after surgery Low DROSHA High DROSHA 0 00 Nº at Risk Events Months 0 0 Low DROSHA High DROSHA Downloaded from at Pennsylvania State University on February,
22 Page of Carcinogenesis G % of Survival,0,,,,,0 0 Second Validation Cohort: Stage I-II lung AD P= Months after surgery High DICER Low DICER Nº at Risk Events Months 0 0 Low DICER 0 High DICER % of Survival,0,,,,,0 0 P= 0.00 Months after surgery Nº at Risk Events Months 0 0 Low DROSHA 0 High DROSHA Low DROSHA High DROSHA 00 Downloaded from at Pennsylvania State University on February,
23 Page of Fig.. A B Relative mirna expression 0 SCC Relative mirna expression 0 SCC ADC ADC P=0.00 P=0.00 P=0.0 P=0. P=0. let-a mir-0c mir- mir- mir- P=0.0 Low DICER P=0.00 P=0.00 Low DROSHA P=0.00 let-a mir- let-a mir- hsa-let-a mir- SCC ADC SCC ADC Low DICER.±0. 0.±0..±0..0±0. Low DROSHA.±0. 0.±0..±..±0. Downloaded from at Pennsylvania State University on February,
24 Page of Carcinogenesis Supplementary Figure. mirna biogenesis pathway illustrative overview. micrornas (mirnas) are transcribed to produce a nucleotide transcripts, called pri-mirna. It is cropped to form a pre-mirna hairpin (-00 nucleotides) which is transported to the cytoplasm through an export complex. Finally, the pre-mirna is processed to produce two mirna strands, a mature mirna sequence, approximately -0 nucleotides in length, and its short-lived complementary sequence, which is denoted mir* and sometime called the passenger strand. The thermodynamic stability of the mirna duplex termini and the identity of the nucleotides in the overhang determine which of the strands is incorporated into the RNA-inducing silencing complex (RISC). RISC is thought to direct mirna-mediated destabilization or mirna-mediated translational repression of mirna without perfectly complementary mrna targets. Partial complementarity mirna encoding gene DROSHA pri-mirna NUCLEUS GEMIN GEMIN AGO - mature mirna CYTOPLASM RISC RNA Pol II DGCR pre-mirna XPO TRBP DICER mir/mir* duplex RAN Perfect complementarity ORF AAAAA ORF AAAAA Translational repression Splicing DROSHA-independent Cleavage of target mrna DICER-independent AGO Downloaded from at Pennsylvania State University on February,
25 Page of Supplementary Figure : Immunohistochemical staining of NSCLC samples. These assays were performed using formalin-fixed, paraffin-embedded lung cancer tissues (FFPE). Immunohistochemistry was performed on a subset of lung cancer biopsies selected due to their varying levels of DICER (upper panels) and DROSHA (lower panels) mrna expression. Results were consistent with those obtained in DICER and DROSHA mrna expression levels by q-rt-pcr. We did not find any significant difference in the expression of DICER or DROSHA between SCC and ADC histology. DICER DROSHA High expression Low expression Downloaded from at Pennsylvania State University on February,
26 Page of Carcinogenesis Supplementary Figure : As compared with other subgroups (low DICER and high DROSHA expression), patients with tumors with high levels of DICER mrna and low levels of DROSHA mrna were associated with an increased median survival (not reached, vs.. months; P=0.0). Also, tumors with low DICER and low DROSHA mrna levels were associated with an increased median survival as compared with tumors with low DICER and high DROSHA mrna levels (not reached vs.. months; P= 0.0). % of Survival,0,,,, 0,0 0 P= 0.0 High DICER Low DROSHA Low DICER Low DROSHA Months after surgery 0 High DICER High DROSHA Low DICER High DROSHA 00 Nº at Risk Events Months 0 0 Low DICER, Low DROSHA High DICER, High DROSHA 0 Low DICER, High DROSHA High DICER, Low DROSHA 0 Log Rank (significance) Low DICER Low DROSHA High DICER High DROSHA Low DICER High DROSHA High DICER, High DROSHA 0. (0.0) Low DICER, High DROSHA. (0.0) 0. (0.) High DICER, Low DROSHA 0. (0.). (0.0). (0.0) Downloaded from at Pennsylvania State University on February,
27 Page of Supplementary Table. Distribution of DICER and DROSHA mrna levels in lung cancer tumors. N (%) N= Median Ratio (range) Individual Low DICER (.) 0. ± 0.0 (0.-0.) High DICER (.). ± 0.0 (.0-.) Low DROSHA () 0. ± 0.0 (0.-.00) High DROSHA (). ± 0. (.0-.) Joint Low DICER and DROSHA () Low DICER and High DROSHA () High DICER and DROSHA () High DICER and low DROSHA () Downloaded from at Pennsylvania State University on February,
28 Page of Carcinogenesis Supplementary Table. Downregulation of mirnas in NSCLC samples compared to normal tissue. % of total cohort % of ADC % of SCC hsa-let-a... mir-0c..0. mir-..0. mir-... mir-... Downloaded from at Pennsylvania State University on February,
29 Page of Supplementary Table. Correlation coefficients between micrornas, DICER and DROSHA expression levels. DICER ρ a DROSHA ρ a hsa-let-a ρ a mir-0c ρ a mir- ρ a mir- ρ a mir- ρ a DICER * -0.0** -0.* DROSHA -0.** ** hsa-let-a 0.** 0.0** 0. 0.** mir-0c 0.** 0. 0.** mir * mir- 0.** mir- a ρ= Spearman s coefficient. N= samples. *p< 0.0, **p< 0.0. Downloaded from at Pennsylvania State University on February,
mirna Dr. S Hosseini-Asl
mirna Dr. S Hosseini-Asl 1 2 MicroRNAs (mirnas) are small noncoding RNAs which enhance the cleavage or translational repression of specific mrna with recognition site(s) in the 3 - untranslated region
More informationmicrorna Presented for: Presented by: Date:
microrna Presented for: Presented by: Date: 2 micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved Regulate gene expression by binding complementary regions at 3 regions
More informationMicroRNA expression profiling and functional analysis in prostate cancer. Marco Folini s.c. Ricerca Traslazionale DOSL
MicroRNA expression profiling and functional analysis in prostate cancer Marco Folini s.c. Ricerca Traslazionale DOSL What are micrornas? For almost three decades, the alteration of protein-coding genes
More informationSupplementary Material
Supplementary Material Identification of mir-187 and mir-182 as biomarkers for early diagnosis and prognosis in prostate cancer patients treated with radical prostatectomy Irene Casanova-Salas 1, José
More informationMicroRNA dysregulation in cancer. Systems Plant Microbiology Hyun-Hee Lee
MicroRNA dysregulation in cancer Systems Plant Microbiology Hyun-Hee Lee Contents 1 What is MicroRNA? 2 mirna dysregulation in cancer 3 Summary What is MicroRNA? What is MicroRNA? MicroRNAs (mirnas) -
More informationMicroRNA and Male Infertility: A Potential for Diagnosis
Review Article MicroRNA and Male Infertility: A Potential for Diagnosis * Abstract MicroRNAs (mirnas) are small non-coding single stranded RNA molecules that are physiologically produced in eukaryotic
More informationPatnaik SK, et al. MicroRNAs to accurately histotype NSCLC biopsies
Patnaik SK, et al. MicroRNAs to accurately histotype NSCLC biopsies. 2014. Supplemental Digital Content 1. Appendix 1. External data-sets used for associating microrna expression with lung squamous cell
More informationAndrogen Receptor Expression in Renal Cell Carcinoma: A New Actionable Target?
Androgen Receptor Expression in Renal Cell Carcinoma: A New Actionable Target? New Frontiers in Urologic Oncology Juan Chipollini, MD Clinical Fellow Department of Genitourinary Oncology Moffitt Cancer
More informationCorporate Medical Policy
Corporate Medical Policy Microarray-based Gene Expression Testing for Cancers of Unknown File Name: Origination: Last CAP Review: Next CAP Review: Last Review: microarray-based_gene_expression_testing_for_cancers_of_unknown_primary
More informationSupplementary Figure S1 Expression of mir-181b in EOC (A) Kaplan-Meier
Supplementary Figure S1 Expression of mir-181b in EOC (A) Kaplan-Meier curves for progression-free survival (PFS) and overall survival (OS) in a cohort of patients (N=52) with stage III primary ovarian
More informationDownregulation of serum mir-17 and mir-106b levels in gastric cancer and benign gastric diseases
Brief Communication Downregulation of serum mir-17 and mir-106b levels in gastric cancer and benign gastric diseases Qinghai Zeng 1 *, Cuihong Jin 2 *, Wenhang Chen 2, Fang Xia 3, Qi Wang 3, Fan Fan 4,
More informationCorrelation between expression and significance of δ-catenin, CD31, and VEGF of non-small cell lung cancer
Correlation between expression and significance of δ-catenin, CD31, and VEGF of non-small cell lung cancer X.L. Liu 1, L.D. Liu 2, S.G. Zhang 1, S.D. Dai 3, W.Y. Li 1 and L. Zhang 1 1 Thoracic Surgery,
More informationExpression of mir-1294 is downregulated and predicts a poor prognosis in gastric cancer
European Review for Medical and Pharmacological Sciences 2018; 22: 5525-5530 Expression of mir-1294 is downregulated and predicts a poor prognosis in gastric cancer Y.-X. SHI, B.-L. YE, B.-R. HU, X.-J.
More informationRNA preparation from extracted paraffin cores:
Supplementary methods, Nielsen et al., A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor positive breast cancer.
More informationHigh expression of fibroblast activation protein is an adverse prognosticator in gastric cancer.
Biomedical Research 2017; 28 (18): 7779-7783 ISSN 0970-938X www.biomedres.info High expression of fibroblast activation protein is an adverse prognosticator in gastric cancer. Hu Song 1, Qi-yu Liu 2, Zhi-wei
More informationBi 8 Lecture 17. interference. Ellen Rothenberg 1 March 2016
Bi 8 Lecture 17 REGulation by RNA interference Ellen Rothenberg 1 March 2016 Protein is not the only regulatory molecule affecting gene expression: RNA itself can be negative regulator RNA does not need
More informationhe micrornas of Caenorhabditis elegans (Lim et al. Genes & Development 2003)
MicroRNAs: Genomics, Biogenesis, Mechanism, and Function (D. Bartel Cell 2004) he micrornas of Caenorhabditis elegans (Lim et al. Genes & Development 2003) Vertebrate MicroRNA Genes (Lim et al. Science
More informationmicrornas (mirna) and Biomarkers
micrornas (mirna) and Biomarkers Small RNAs Make Big Splash mirnas & Genome Function Biomarkers in Cancer Future Prospects Javed Khan M.D. National Cancer Institute EORTC-NCI-ASCO November 2007 The Human
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationHigh AU content: a signature of upregulated mirna in cardiac diseases
https://helda.helsinki.fi High AU content: a signature of upregulated mirna in cardiac diseases Gupta, Richa 2010-09-20 Gupta, R, Soni, N, Patnaik, P, Sood, I, Singh, R, Rawal, K & Rani, V 2010, ' High
More informationEvolution of Pathology
1 Traditional pathology Molecular pathology 2 Evolution of Pathology Gross Pathology Cellular Pathology Morphologic Pathology Molecular/Predictive Pathology Antonio Benivieni (1443-1502): First autopsy
More informationSupplementary Figure 1
Supplementary Figure 1 Asymmetrical function of 5p and 3p arms of mir-181 and mir-30 families and mir-142 and mir-154. (a) Control experiments using mirna sensor vector and empty pri-mirna overexpression
More informationSupplemental Figure S1. RANK expression on human lung cancer cells.
Supplemental Figure S1. RANK expression on human lung cancer cells. (A) Incidence and H-Scores of RANK expression determined from IHC in the indicated primary lung cancer subgroups. The overall expression
More informationMicroRNAs, RNA Modifications, RNA Editing. Bora E. Baysal MD, PhD Oncology for Scientists Lecture Tue, Oct 17, 2017, 3:30 PM - 5:00 PM
MicroRNAs, RNA Modifications, RNA Editing Bora E. Baysal MD, PhD Oncology for Scientists Lecture Tue, Oct 17, 2017, 3:30 PM - 5:00 PM Expanding world of RNAs mrna, messenger RNA (~20,000) trna, transfer
More informationOriginal Article CREPT expression correlates with esophageal squamous cell carcinoma histological grade and clinical outcome
Int J Clin Exp Pathol 2017;10(2):2030-2035 www.ijcep.com /ISSN:1936-2625/IJCEP0009456 Original Article CREPT expression correlates with esophageal squamous cell carcinoma histological grade and clinical
More informationCorrelation between estrogen receptor β expression and the curative effect of endocrine therapy in breast cancer patients
1568 Correlation between estrogen receptor β expression and the curative effect of endocrine therapy in breast cancer patients LIYING GUO 1, YU ZHANG 2, WEI ZHANG 3 and DILIMINA YILAMU 1 1 Department of
More informationV16: involvement of micrornas in GRNs
What are micrornas? V16: involvement of micrornas in GRNs How can one identify micrornas? What is the function of micrornas? Elisa Izaurralde, MPI Tübingen Huntzinger, Izaurralde, Nat. Rev. Genet. 12,
More informationType of file: PDF Size of file: 0 KB Title of file for HTML: Supplementary Information Description: Supplementary Figures
Type of file: PDF Size of file: 0 KB Title of file for HTML: Supplementary Information Description: Supplementary Figures Supplementary Figure 1 mir-128-3p is highly expressed in chemoresistant, metastatic
More informationmicrorna PCR System (Exiqon), following the manufacturer s instructions. In brief, 10ng of
SUPPLEMENTAL MATERIALS AND METHODS Quantitative RT-PCR Quantitative RT-PCR analysis was performed using the Universal mircury LNA TM microrna PCR System (Exiqon), following the manufacturer s instructions.
More informationSSM signature genes are highly expressed in residual scar tissues after preoperative radiotherapy of rectal cancer.
Supplementary Figure 1 SSM signature genes are highly expressed in residual scar tissues after preoperative radiotherapy of rectal cancer. Scatter plots comparing expression profiles of matched pretreatment
More informationMicroRNA in Cancer Karen Dybkær 2013
MicroRNA in Cancer Karen Dybkær RNA Ribonucleic acid Types -Coding: messenger RNA (mrna) coding for proteins -Non-coding regulating protein formation Ribosomal RNA (rrna) Transfer RNA (trna) Small nuclear
More informationAssociation between downexpression of mir-1301 and poor prognosis in patients with glioma
European Review for Medical and Pharmacological Sciences 2017; 21: 4298-4303 Association between downexpression of mir-1301 and poor prognosis in patients with glioma Q.-L. BAI, C.-W. HU, X.-R. WANG, G.-F.
More informationMir-595 is a significant indicator of poor patient prognosis in epithelial ovarian cancer
European Review for Medical and Pharmacological Sciences 2017; 21: 4278-4282 Mir-595 is a significant indicator of poor patient prognosis in epithelial ovarian cancer Q.-H. ZHOU 1, Y.-M. ZHAO 2, L.-L.
More information95% CI: , P=0.037).
Biomedical Research 2017; 28 (21): 9248-9252 Reduced expression level of mir-205 predicts poor prognosis in Qiang Yang 1*#, Peng Sun 2#, Haotian Feng 1, Xin Li 1, Jianmin Li 1 1 Department of Orthopedics,
More informationSupplementary webappendix
Supplementary webappendix This webappendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Kratz JR, He J, Van Den Eeden SK, et
More informationAssociation of mir-21 with esophageal cancer prognosis: a meta-analysis
Association of mir-21 with esophageal cancer prognosis: a meta-analysis S.-W. Wen 1, Y.-F. Zhang 1, Y. Li 1, Z.-X. Liu 2, H.-L. Lv 1, Z.-H. Li 1, Y.-Z. Xu 1, Y.-G. Zhu 1 and Z.-Q. Tian 1 1 Department of
More informationRefining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis
5/17/13 Refining Prognosis of Early Stage Lung Cancer by Molecular Features (Part 2): Early Steps in Molecularly Defined Prognosis Johannes Kratz, MD Post-doctoral Fellow, Thoracic Oncology Laboratory
More informationProfiles of gene expression & diagnosis/prognosis of cancer. MCs in Advanced Genetics Ainoa Planas Riverola
Profiles of gene expression & diagnosis/prognosis of cancer MCs in Advanced Genetics Ainoa Planas Riverola Gene expression profiles Gene expression profiling Used in molecular biology, it measures the
More informationProsigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY
Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY Methodology The test is based on the reported 50-gene classifier algorithm originally named PAM50 and is performed on the ncounter Dx Analysis System
More informationProsigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY
Prosigna BREAST CANCER PROGNOSTIC GENE SIGNATURE ASSAY GENE EXPRESSION PROFILING WITH PROSIGNA What is Prosigna? Prosigna Breast Cancer Prognostic Gene Signature Assay is an FDA-approved assay which provides
More informationNational Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant
National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant Reporting Period July 1, 2011 June 30, 2012 Formula Grant Overview The National Surgical
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More informationExpression of mir-148/152 Family as Potential Biomarkers in Non-Small-Cell Lung Cancer
e-issn 1643-375 Med Sci Monit, 215; 21: 1155-1161 DOI: 1.12659/MSM.89294 Received: 214.11.3 Accepted: 214.11.13 Published: 215.4.23 Expression of mir-148/152 Family as Potential Biomarkers in Non-Small-Cell
More informationOriginal Article Up-regulation of mir-10a and down-regulation of mir-148b serve as potential prognostic biomarkers for osteosarcoma
Int J Clin Exp Pathol 2016;9(1):186-190 www.ijcep.com /ISSN:1936-2625/IJCEP0018032 Original Article Up-regulation of mir-10a and down-regulation of mir-148b serve as potential prognostic biomarkers for
More informationCell lines and tissue samples. The 18 human NSCLC cell lines used in this. study included eight adenocarcinoma cell lines (ADCs; A427, A549, LC319,
Supplementary Materials and Methods Cell lines and tissue samples. The 18 human NSCLC cell lines used in this study included eight adenocarcinoma cell lines (ADCs; A427, A549, LC319, NCI-H1373, PC-3, PC-9,
More informationPost-transcriptional regulation of an intronic microrna
Post-transcriptional regulation of an intronic microrna Carl Novina Dana-Farber Cancer Institute Harvard Medical School Broad Institute of Harvard and MIT Qiagen Webinar 05-17-11 Outline 1. The biology
More informationCellular MicroRNA and P Bodies Modulate Host-HIV-1 Interactions. 指導教授 : 張麗冠博士 演講者 : 黃柄翰 Date: 2009/10/19
Cellular MicroRNA and P Bodies Modulate Host-HIV-1 Interactions 指導教授 : 張麗冠博士 演講者 : 黃柄翰 Date: 2009/10/19 1 MicroRNA biogenesis 1. Pri mirna: primary mirna 2. Drosha: RNaseIII 3. DCR 1: Dicer 1 RNaseIII
More informationTitle page. Title: MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in
Title page Title: MicroRNA- Controls Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma Authors Manabu Mikamori, Daisaku Yamada, Hidetoshi Eguchi, Shinichiro Hasegawa, Tomoya
More informationLow levels of serum mir-99a is a predictor of poor prognosis in breast cancer
Low levels of serum mir-99a is a predictor of poor prognosis in breast cancer J. Li 1, Z.J. Song 2, Y.Y. Wang 1, Y. Yin 1, Y. Liu 1 and X. Nan 1 1 Tumor Research Department, Shaanxi Provincial Tumor Hospital,
More informationTranslational Application of microrna Profiling to Detect Non-Small Cell Lung Cancers. Jennifer Gyoba
Translational Application of microrna Profiling to Detect Non-Small Cell Lung Cancers by Jennifer Gyoba A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science
More informationTitle: Synuclein Gamma Predicts Poor Clinical Outcome in Colon Cancer with Normal Levels of Carcinoembryonic Antigen
Author's response to reviews Title: Synuclein Gamma Predicts Poor Clinical Outcome in Colon Cancer with Normal Levels of Carcinoembryonic Antigen Authors: Caiyun Liu (liucaiyun23@yahoo.com.cn) Bin Dong
More informationBin Liu, Lei Yang, Binfang Huang, Mei Cheng, Hui Wang, Yinyan Li, Dongsheng Huang, Jian Zheng,
The American Journal of Human Genetics, Volume 91 Supplemental Data A Functional Copy-Number Variation in MAPKAPK2 Predicts Risk and Survival of Lung Cancer Bin Liu, Lei Yang, Binfang Huang, Mei Cheng,
More informationAlternative RNA processing: Two examples of complex eukaryotic transcription units and the effect of mutations on expression of the encoded proteins.
Alternative RNA processing: Two examples of complex eukaryotic transcription units and the effect of mutations on expression of the encoded proteins. The RNA transcribed from a complex transcription unit
More informationreported to underlie diverse aspects of biology, including developmental timing, differentiation, proliferation, cell death, and metabolism.
1100 MicroRNA in Cancer: The Involvement of Aberrant MicroRNA Biogenesis Regulatory Pathways Genes & Cancer 1(11) 1100 1114 The Author(s) 2011 Reprints and permission: sagepub.com/journalspermissions.nav
More informationCircular RNAs (circrnas) act a stable mirna sponges
Circular RNAs (circrnas) act a stable mirna sponges cernas compete for mirnas Ancestal mrna (+3 UTR) Pseudogene RNA (+3 UTR homolgy region) The model holds true for all RNAs that share a mirna binding
More informationThe Biology and Genetics of Cells and Organisms The Biology of Cancer
The Biology and Genetics of Cells and Organisms The Biology of Cancer Mendel and Genetics How many distinct genes are present in the genomes of mammals? - 21,000 for human. - Genetic information is carried
More informationRegulation of Gene Expression in Eukaryotes
Ch. 19 Regulation of Gene Expression in Eukaryotes BIOL 222 Differential Gene Expression in Eukaryotes Signal Cells in a multicellular eukaryotic organism genetically identical differential gene expression
More informationNational Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant
National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant Reporting Period July 1, 2012 June 30, 2013 Formula Grant Overview The National Surgical
More informationCircHIPK3 is upregulated and predicts a poor prognosis in epithelial ovarian cancer
European Review for Medical and Pharmacological Sciences 2018; 22: 3713-3718 CircHIPK3 is upregulated and predicts a poor prognosis in epithelial ovarian cancer N. LIU 1, J. ZHANG 1, L.-Y. ZHANG 1, L.
More informationDecreased expression of mir-490-3p in osteosarcoma and its clinical significance
European Review for Medical and Pharmacological Sciences Decreased expression of mir-490-3p in osteosarcoma and its clinical significance B. TANG, C. LIU, Q.-M. ZHANG, M. NI Department of Orthopedics,
More informationApplications of IHC. Determination of the primary site in metastatic tumors of unknown origin
Applications of IHC Determination of the primary site in metastatic tumors of unknown origin Classification of tumors that appear 'undifferentiated' by standard light microscopy Precise classification
More informationCancer Cell Research 17 (2018)
Available at http:// www.cancercellresearch.org ISSN 2161-2609 Prognostic value of MicroRNA-21 in non-small cell lung cancer: a meta-analysis Fei Xu, Leina Ma, Lingxin Feng, Yinjie Wu, Xiaoyan Xu, Zhuang
More informationCancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC
Cancers of unknown primary : Knowing the unknown Prof. Ahmed Hossain Professor of Medicine SSMC Definition Cancers of unknown primary site (CUPs) Represent a heterogeneous group of metastatic tumours,
More informationGESIDA 2018 ANTIRETROVIRAL TREATMENT MAINTENANCE STRATEGIES AND BLOOD TELOMERE LENGTH CHANGE
ANTIRETROVIRAL TREATMENT MAINTENANCE STRATEGIES AND BLOOD TELOMERE LENGTH CHANGE Rocío Montejano 1, Natalia Stella-Ascariz 1, Susana Monge 1, Jose I Bernardino 1, Ignacio Perez-Valero 1, Marisa Montes
More informationGene expression profiling predicts clinical outcome of prostate cancer. Gennadi V. Glinsky, Anna B. Glinskii, Andrew J. Stephenson, Robert M.
SUPPLEMENTARY DATA Gene expression profiling predicts clinical outcome of prostate cancer Gennadi V. Glinsky, Anna B. Glinskii, Andrew J. Stephenson, Robert M. Hoffman, William L. Gerald Table of Contents
More informationExpression of long non-coding RNA linc-itgb1 in breast cancer and its influence on prognosis and survival
European Review for Medical and Pharmacological Sciences 2017; 21: 3397-3401 Expression of long non-coding RNA linc-itgb1 in breast cancer and its influence on prognosis and survival W.-X. LI 1, R.-L.
More informationClinical significance of serum mir-196a in cervical intraepithelial neoplasia and cervical cancer
Clinical significance of serum mir-196a in cervical intraepithelial neoplasia and cervical cancer P. Liu 1, F. Xin 1 and C.F. Ma 2 1 Department of Obstetrics & Gynecology, Baoding Second Central Hospital,
More informationThe Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine Carcinoma (LCNC)
The Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine Carcinoma (LCNC) Disclosure None Background Torino, Italy LCNC Rare tumor (2% to 3% all resected primary lung cancers) Preoperative
More informationRNA interference (RNAi)
RN interference (RNi) Natasha aplen ene Silencing Section Office of Science and Technology Partnerships Office of the Director enter for ancer Research National ancer Institute ncaplen@mail.nih.gov Plants
More informationGENE EXPRESSION AND microrna PROFILING IN LYMPHOMAS. AN INTEGRATIVE GENOMICS ANALYSIS
GENE EXPRESSION AND microrna PROFILING IN LYMPHOMAS. AN INTEGRATIVE GENOMICS ANALYSIS Dra. Margarita Sánchez-Beato Lymphoma Group Molecular Pathology Programme CNIO Agilent Microarray and Sequencing Roadshow,
More informationDetection of Anaplastic Lymphoma Kinase (ALK) gene in Non-Small Cell lung Cancer (NSCLC) By CISH Technique
Cancer and Clinical Oncology; Vol. 7, No. 1; 2018 ISSN 1927-4858 E-ISSN 1927-4866 Published by Canadian Center of Science and Education Detection of Anaplastic Lymphoma Kinase (ALK) gene in Non-Small Cell
More informationDeciphering the Role of micrornas in BRD4-NUT Fusion Gene Induced NUT Midline Carcinoma
www.bioinformation.net Volume 13(6) Hypothesis Deciphering the Role of micrornas in BRD4-NUT Fusion Gene Induced NUT Midline Carcinoma Ekta Pathak 1, Bhavya 1, Divya Mishra 1, Neelam Atri 1, 2, Rajeev
More informationImplications of microrna-197 downregulated expression in esophageal cancer with poor prognosis
Implications of microrna-197 downregulated expression in esophageal cancer with poor prognosis T.-Y. Wang 1, S.-G. Liu 2, B.-S. Zhao 2, B. Qi 2, X.-G. Qin 2 and W.-J. Yao 2 1 Department of Biochemistry
More informationQuality ID #395: Lung Cancer Reporting (Biopsy/Cytology Specimens) National Quality Strategy Domain: Communication and Care Coordination
Quality ID #395: Lung Cancer Reporting (Biopsy/Cytology Specimens) National Quality Strategy Domain: Communication and Care Coordination 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE:
More informationImpact of Prognostic Factors
Melanoma Prognostic Factors: where we started, where are we going? Impact of Prognostic Factors Staging Management Surgical intervention Adjuvant treatment Suraj Venna, MD Assistant Clinical Professor,
More informationThe BCL11A-XL expression predicts relapse in squamous cell carcinoma and large cell carcinoma
Original Article The BCL11A-XL expression predicts relapse in squamous cell carcinoma and large cell carcinoma Na Zhang 1,2, Ben-Yuan Jiang 2, Xu-Chao Zhang 2, Zhi Xie 2, Jian Su 2, Qi Zhang 2, Jie-Fei
More informationThe 16th KJC Bioinformatics Symposium Integrative analysis identifies potential DNA methylation biomarkers for pan-cancer diagnosis and prognosis
The 16th KJC Bioinformatics Symposium Integrative analysis identifies potential DNA methylation biomarkers for pan-cancer diagnosis and prognosis Tieliu Shi tlshi@bio.ecnu.edu.cn The Center for bioinformatics
More informationPatient characteristics of training and validation set. Patient selection and inclusion overview can be found in Supp Data 9. Training set (103)
Roepman P, et al. An immune response enriched 72-gene prognostic profile for early stage Non-Small- Supplementary Data 1. Patient characteristics of training and validation set. Patient selection and inclusion
More informationTHE STUDY ON RELATIONSHIP BETWEEN CIGARETTE SMOKING AND THE p53 PROTEIN AND P21 PROTEIN EXPRESSION IN NON-SMALL LUNG CANCER
( Thmese Journal of ('ancer Research 8(3): 187-19L 1996. THE STUDY ON RELATIONSHIP BETWEEN CIGARETTE SMOKING AND THE p53 PROTEIN AND P21 PROTEIN EXPRESSION IN NON-SMALL LUNG CANCER ZhouBaosen )~j'#:~ lleanguang
More informationPhenomena first observed in petunia
Vectors for RNAi Phenomena first observed in petunia Attempted to overexpress chalone synthase (anthrocyanin pigment gene) in petunia. (trying to darken flower color) Caused the loss of pigment. Bill Douherty
More informationOnly Estrogen receptor positive is not enough to predict the prognosis of breast cancer
Young Investigator Award, Global Breast Cancer Conference 2018 Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer ㅑ Running head: Revisiting estrogen positive tumors
More informationmir-218 tissue expression level is associated with aggressive progression of gastric cancer
mir-218 tissue expression level is associated with aggressive progression of gastric cancer X.X. Wang 1, S.J. Ge 2, X.L. Wang 2, L.X. Jiang 1, M.F. Sheng 2 and J.J. Ma 2 1 Department of General Surgery,
More informationINFLAMMATION AND CANCER: INTERACTION OF THE CYTOKINE, p53 AND MICRORNA PATHWAYS
INFLAMMATION AND CANCER: INTERACTION OF THE CYTOKINE, p53 AND MICRORNA PATHWAYS Curtis Harris Laboratory of Human Carcinogenesis NCI Bethesda, MD 20896 Curtis_Harris@NIH.GOV CHRONIC INFLAMMATION AND INFECTION
More informationMicroRNAs: novel regulators in skin research
MicroRNAs: novel regulators in skin research Eniko Sonkoly, Andor Pivarcsi KI, Department of Medicine, Unit of Dermatology and Venerology What are micrornas? Small, ~21-mer RNAs 1993: The first mirna discovered,
More informationOn the Reproducibility of TCGA Ovarian Cancer MicroRNA Profiles
On the Reproducibility of TCGA Ovarian Cancer MicroRNA Profiles Ying-Wooi Wan 1,2,4, Claire M. Mach 2,3, Genevera I. Allen 1,7,8, Matthew L. Anderson 2,4,5 *, Zhandong Liu 1,5,6,7 * 1 Departments of Pediatrics
More informationIdentification of novel gene expression signature in lung adenocarcinoma by using next-generation sequencing data and bioinformatics analysis
/, 2017, Vol. 8, (No. 62), pp: 104831-104854 Identification of novel gene expression signature in lung adenocarcinoma by using next-generation sequencing data and bioinformatics analysis Ya-Ling Hsu 1,*,
More informationQuality ID #395: Lung Cancer Reporting (Biopsy/Cytology Specimens) National Quality Strategy Domain: Communication and Care Coordination
Quality ID #395: Lung Cancer Reporting (Biopsy/Cytology Specimens) National Quality Strategy Domain: Communication and Care Coordination 2018 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY MEASURE TYPE:
More informationContemporary Classification of Breast Cancer
Contemporary Classification of Breast Cancer Laura C. Collins, M.D. Vice Chair of Anatomic Pathology Professor of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA Outline
More informationSupplementary Figure S1. Venn diagram analysis of mrna microarray data and mirna target analysis. (a) Western blot analysis of T lymphoblasts (CLS)
Supplementary Figure S1. Venn diagram analysis of mrna microarray data and mirna target analysis. (a) Western blot analysis of T lymphoblasts (CLS) and their exosomes (EXO) in resting (REST) and activated
More informationW J C O. World Journal of Clinical Oncology. MicroRNAs as lung cancer biomarkers. Abstract INTRODUCTION TOPIC HIGHLIGHT
W J C O World Journal of Clinical Oncology Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.5306/wjco.v5.i4.604 World J Clin Oncol 2014 October
More informationmir-206 Expression Is Down-regulated in Estrogen Receptor A Positive Human Breast Cancer
Priority Report mir-206 Expression Is Down-regulated in Estrogen Receptor A Positive Human Breast Cancer Naoto Kondo, Tatsuya Toyama, Hiroshi Sugiura, Yoshitaka Fujii, and Hiroko Yamashita Oncology, Immunology,
More informationOriginal Article Reduced serum mir-138 is associated with poor prognosis of head and neck squamous cell carcinoma
Int J Clin Exp Pathol 2017;10(10):10276-10281 www.ijcep.com /ISSN:1936-2625/IJCEP0059849 Original Article Reduced serum mir-138 is associated with poor prognosis of head and neck squamous cell carcinoma
More informationSupplementary Information Titles Journal: Nature Medicine
Supplementary Information Titles Journal: Nature Medicine Article Title: Corresponding Author: Supplementary Item & Number Supplementary Fig.1 Fig.2 Fig.3 Fig.4 Fig.5 Fig.6 Fig.7 Fig.8 Fig.9 Fig. Fig.11
More informationHigh Expression of Forkhead Box Protein C2 is Related to Poor Prognosis in Human Gliomas
DOI:http://dx.doi.org/10.7314/APJCP.2014.15.24.10621 RESEARCH ARTICLE High Expression of Forkhead Box Protein C2 is Related to Poor Prognosis in Human Gliomas Yao-Wu Wang 1, Chun-Li Yin 2, Hong-Yi Zhang
More informationBiomarker development in the era of precision medicine. Bei Li, Interdisciplinary Technical Journal Club
Biomarker development in the era of precision medicine Bei Li, 23.08.2016 Interdisciplinary Technical Journal Club The top ten highest-grossing drugs in the United States help between 1 in 25 and 1 in
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More informationCytokeratin 5/6 expression in bladder cancer: association with clinicopathologic parameters and prognosis
https://doi.org/10.1186/s13104-018-3319-4 BMC Research Notes RESEARCH NOTE Open Access Cytokeratin 5/6 expression in bladder cancer: association with clinicopathologic parameters and prognosis Atif Ali
More informationSupervivencia a 5 años de Pacientes Coinfectados por VHC-VIH Trasplantados Hepáticos: un Estudio de Casos y Controles
I Congreso de GESIDA Madrid, 21-24 de Octubre del 2009. Supervivencia a 5 años de Pacientes Coinfectados por VHC-VIH Trasplantados Hepáticos: un Estudio de Casos y Controles José M. Miró, 1 Miguel Montejo,
More informationPredictive Assays in Radiation Therapy
Outline Predictive Assays in Radiation Therapy Radiation Biology Introduction Early predictive assays Recent trends in predictive assays Examples for specific tumors Summary Lecture 4-23-2014 Introduction
More informationAssessment performed on Tuesday, July 29, 2014, at Lions Gate Hospital, North Vancouver
Assessors report for ciqc Run 37: BRAF V600E (April 2014) Assessors: B Gilks, R Wolber, K Ung, P Tavassoli, J Garratt and J Won (recorder) Assessment performed on Tuesday, July 29, 2014, at Lions Gate
More information